A tumornekrózis-faktor-alfa-gátlók hatékonysága perianalis fisztulázó Crohn-betegségben

Translated title of the contribution: Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease

Renáta Bor, Klaudia Farkas, Anita Bálint, Mónika Szucs, Szabolcs Ábrahám, Gellért Baradnay, T. Wittmann, Zoltán Szepes, F. Nagy, T. Molnár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Tumor necrosis factor-alpha inhibitors are increasingly used in the treatment of severe Crohn's disease. Aim: The aim of the authors was to assess retrospectively the short and long term efficacy of tumor necrosis factor-alpha inhibitors in fistulising Crohn's disease. Method: Responses to therapy was determined using Crohn's Disease Activity Index, Perianal Disease Activity Index, the rate of complete fistula closure and the additional surgical procedures during biological therapy. Results: After 12 weeks the perianal activity was decreased in more than 80% of the cases, and the complete remission rate was about 60%. After one year of therapy about one third of the patients had fistula closure, but after cessation of the biological therapy recurrence of fistulas was detected in every second patient. In most cases additional immunosuppressive therapy was necessary during biological treatment. During the one-year therapy period additional surgical treatments were performed in 45% of patients; seton insertion and abscess drainage were the most frequent procedures. Conclusions: Tumor necrosis factor-alpha inhibitor therapy is effective in the treatment of perianal Crohn's disease, however, additional immunosuppressive drugs and rectum sparing surgical procedures were necessary during the one-year treatment period. Because of the high rate of fistula recurrence, long term tumor necrosis factor-alpha treatment may be useful.

Original languageHungarian
Pages (from-to)1943-1948
Number of pages6
JournalOrvosi Hetilap
Volume154
Issue number49
DOIs
Publication statusPublished - Dec 1 2013

Fingerprint

Crohn Disease
Tumor Necrosis Factor-alpha
Fistula
Therapeutics
Biological Therapy
Immunosuppressive Agents
Recurrence
Rectum
Abscess
Drainage

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A tumornekrózis-faktor-alfa-gátlók hatékonysága perianalis fisztulázó Crohn-betegségben. / Bor, Renáta; Farkas, Klaudia; Bálint, Anita; Szucs, Mónika; Ábrahám, Szabolcs; Baradnay, Gellért; Wittmann, T.; Szepes, Zoltán; Nagy, F.; Molnár, T.

In: Orvosi Hetilap, Vol. 154, No. 49, 01.12.2013, p. 1943-1948.

Research output: Contribution to journalArticle

Bor, R, Farkas, K, Bálint, A, Szucs, M, Ábrahám, S, Baradnay, G, Wittmann, T, Szepes, Z, Nagy, F & Molnár, T 2013, 'A tumornekrózis-faktor-alfa-gátlók hatékonysága perianalis fisztulázó Crohn-betegségben', Orvosi Hetilap, vol. 154, no. 49, pp. 1943-1948. https://doi.org/10.1556/OH.2013.29770
Bor R, Farkas K, Bálint A, Szucs M, Ábrahám S, Baradnay G et al. A tumornekrózis-faktor-alfa-gátlók hatékonysága perianalis fisztulázó Crohn-betegségben. Orvosi Hetilap. 2013 Dec 1;154(49):1943-1948. https://doi.org/10.1556/OH.2013.29770
Bor, Renáta ; Farkas, Klaudia ; Bálint, Anita ; Szucs, Mónika ; Ábrahám, Szabolcs ; Baradnay, Gellért ; Wittmann, T. ; Szepes, Zoltán ; Nagy, F. ; Molnár, T. / A tumornekrózis-faktor-alfa-gátlók hatékonysága perianalis fisztulázó Crohn-betegségben. In: Orvosi Hetilap. 2013 ; Vol. 154, No. 49. pp. 1943-1948.
@article{d32c1ca540f54c8c9ec5055100e536f3,
title = "A tumornekr{\'o}zis-faktor-alfa-g{\'a}tl{\'o}k hat{\'e}konys{\'a}ga perianalis fisztul{\'a}z{\'o} Crohn-betegs{\'e}gben",
abstract = "Introduction: Tumor necrosis factor-alpha inhibitors are increasingly used in the treatment of severe Crohn's disease. Aim: The aim of the authors was to assess retrospectively the short and long term efficacy of tumor necrosis factor-alpha inhibitors in fistulising Crohn's disease. Method: Responses to therapy was determined using Crohn's Disease Activity Index, Perianal Disease Activity Index, the rate of complete fistula closure and the additional surgical procedures during biological therapy. Results: After 12 weeks the perianal activity was decreased in more than 80{\%} of the cases, and the complete remission rate was about 60{\%}. After one year of therapy about one third of the patients had fistula closure, but after cessation of the biological therapy recurrence of fistulas was detected in every second patient. In most cases additional immunosuppressive therapy was necessary during biological treatment. During the one-year therapy period additional surgical treatments were performed in 45{\%} of patients; seton insertion and abscess drainage were the most frequent procedures. Conclusions: Tumor necrosis factor-alpha inhibitor therapy is effective in the treatment of perianal Crohn's disease, however, additional immunosuppressive drugs and rectum sparing surgical procedures were necessary during the one-year treatment period. Because of the high rate of fistula recurrence, long term tumor necrosis factor-alpha treatment may be useful.",
keywords = "adalimumab, biological therapy, infliximab, perianal Crohn's disease",
author = "Ren{\'a}ta Bor and Klaudia Farkas and Anita B{\'a}lint and M{\'o}nika Szucs and Szabolcs {\'A}brah{\'a}m and Gell{\'e}rt Baradnay and T. Wittmann and Zolt{\'a}n Szepes and F. Nagy and T. Moln{\'a}r",
year = "2013",
month = "12",
day = "1",
doi = "10.1556/OH.2013.29770",
language = "Hungarian",
volume = "154",
pages = "1943--1948",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "49",

}

TY - JOUR

T1 - A tumornekrózis-faktor-alfa-gátlók hatékonysága perianalis fisztulázó Crohn-betegségben

AU - Bor, Renáta

AU - Farkas, Klaudia

AU - Bálint, Anita

AU - Szucs, Mónika

AU - Ábrahám, Szabolcs

AU - Baradnay, Gellért

AU - Wittmann, T.

AU - Szepes, Zoltán

AU - Nagy, F.

AU - Molnár, T.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Introduction: Tumor necrosis factor-alpha inhibitors are increasingly used in the treatment of severe Crohn's disease. Aim: The aim of the authors was to assess retrospectively the short and long term efficacy of tumor necrosis factor-alpha inhibitors in fistulising Crohn's disease. Method: Responses to therapy was determined using Crohn's Disease Activity Index, Perianal Disease Activity Index, the rate of complete fistula closure and the additional surgical procedures during biological therapy. Results: After 12 weeks the perianal activity was decreased in more than 80% of the cases, and the complete remission rate was about 60%. After one year of therapy about one third of the patients had fistula closure, but after cessation of the biological therapy recurrence of fistulas was detected in every second patient. In most cases additional immunosuppressive therapy was necessary during biological treatment. During the one-year therapy period additional surgical treatments were performed in 45% of patients; seton insertion and abscess drainage were the most frequent procedures. Conclusions: Tumor necrosis factor-alpha inhibitor therapy is effective in the treatment of perianal Crohn's disease, however, additional immunosuppressive drugs and rectum sparing surgical procedures were necessary during the one-year treatment period. Because of the high rate of fistula recurrence, long term tumor necrosis factor-alpha treatment may be useful.

AB - Introduction: Tumor necrosis factor-alpha inhibitors are increasingly used in the treatment of severe Crohn's disease. Aim: The aim of the authors was to assess retrospectively the short and long term efficacy of tumor necrosis factor-alpha inhibitors in fistulising Crohn's disease. Method: Responses to therapy was determined using Crohn's Disease Activity Index, Perianal Disease Activity Index, the rate of complete fistula closure and the additional surgical procedures during biological therapy. Results: After 12 weeks the perianal activity was decreased in more than 80% of the cases, and the complete remission rate was about 60%. After one year of therapy about one third of the patients had fistula closure, but after cessation of the biological therapy recurrence of fistulas was detected in every second patient. In most cases additional immunosuppressive therapy was necessary during biological treatment. During the one-year therapy period additional surgical treatments were performed in 45% of patients; seton insertion and abscess drainage were the most frequent procedures. Conclusions: Tumor necrosis factor-alpha inhibitor therapy is effective in the treatment of perianal Crohn's disease, however, additional immunosuppressive drugs and rectum sparing surgical procedures were necessary during the one-year treatment period. Because of the high rate of fistula recurrence, long term tumor necrosis factor-alpha treatment may be useful.

KW - adalimumab

KW - biological therapy

KW - infliximab

KW - perianal Crohn's disease

UR - http://www.scopus.com/inward/record.url?scp=84890282289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890282289&partnerID=8YFLogxK

U2 - 10.1556/OH.2013.29770

DO - 10.1556/OH.2013.29770

M3 - Article

C2 - 24292112

AN - SCOPUS:84890282289

VL - 154

SP - 1943

EP - 1948

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 49

ER -